| 1 | The “Small” Clinical Trial: Methods, Analysis, and Interpretation in Acute Care Cardiology | 2.6 | 3 | Citations (PDF) |
| 2 | The relationship of diuretics and dietary sodium in patients with heart failure: an analysis of the SODIUM-HF trial | 2.9 | 2 | Citations (PDF) |
| 3 | Dual Pathway Inhibition in Patients with Atherosclerosis with or without Heart Failure: Insights from the XATOA Registry | 1.6 | 1 | Citations (PDF) |
| 4 | Prediction and Longer-Term Outcomes of All-cause and Cardiovascular Mortality in the HEART-FID Trial | 1.8 | 2 | Citations (PDF) |
| 5 | Impaired Exercise Capacity in High-Risk Diabetic Cardiomyopathy: The ARISE-HF Cardiopulmonary Exercise Testing Subanalysis | 4.4 | 3 | Citations (PDF) |
| 6 | Heterogeneity in Treatment Effects in the Reduction of Dietary Sodium to Less Than 100 mmol in Heart Failure (SODIUM-HF): A Secondary Post Hoc Analysis | 1.8 | 1 | Citations (PDF) |
| 7 | Device Therapy in Patients with Heart Failure: Is Medication Use Optimized and Are We Targeting Those Patients Most Likely to Benefit? | 1.6 | 1 | Citations (PDF) |
| 8 | Revisiting ICD Therapy for Primary Prevention | 4.4 | 1 | Citations (PDF) |
| 9 | iCARDIO Alliance Global Implementation Guidelines on Heart Failure 2025 | 0.9 | 10 | Citations (PDF) |
| 10 | Evaluating the Risk of Hypophosphatemia with Ferric Carboxymaltose and the Recommended Approaches for Management: A Consensus Statement | 2.5 | 9 | Citations (PDF) |
| 11 | Time-to-Diuretics in Acute Heart Failure Management: Striking the Balance Between Speed and Accuracy | 1.8 | 0 | Citations (PDF) |
| 12 | The current state of evidence for sodium and fluid restriction in heart failure | 5.6 | 3 | Citations (PDF) |
| 13 | Hierarchical End Points in Prior Heart Failure Trials and the HEART-FID Trial | 4.4 | 1 | Citations (PDF) |
| 14 | Filling in the Mitral Valve Transcatheter Edge-to-Edge Repair Data Gaps | 2.3 | 0 | Citations (PDF) |
| 15 | The current state of evidence for sodium and fluid restriction in heart failure | 5.6 | 9 | Citations (PDF) |
| 16 | Recurrent Hospitalizations and Response to Vericiguat in Heart Failure and Reduced Ejection Fraction | 4.4 | 11 | Citations (PDF) |
| 17 | HFpEF and sex: understanding the role of sex differences | 1.8 | 14 | Citations (PDF) |
| 18 | Utilizing Quality of Life Adjusted Days Alive and Out of Hospital in Heart Failure Clinical Trials | 4.1 | 4 | Citations (PDF) |
| 19 | Iron Deficiency, Anemia, and Iron Supplementation in Patients With Heart Failure: A Population-Level Study | 4.4 | 8 | Citations (PDF) |
| 20 | WASTED OR WELL SPENT RESOURCES: MAGNESIUM TESTING AND TREATMENT FOR PATIENTS WITH HEART FAILURE | 2.3 | 0 | Citations (PDF) |
| 21 | Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients With Diabetic Cardiomyopathy | 2.3 | 24 | Citations (PDF) |
| 22 | Impact of the method of calculating 30-day readmission rate after hospitalization for heart failure. Data from the VancOuver CoastAL Acute Heart Failure (VOCAL-AHF) registry | 3.7 | 6 | Citations (PDF) |
| 23 | Development and validation of machine learning algorithms based on electrocardiograms for cardiovascular diagnoses at the population level | 10.4 | 33 | Citations (PDF) |
| 24 | Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction | 2.3 | 49 | Citations (PDF) |
| 25 | Racial Differences in Diabetic Cardiomyopathy | 2.3 | 9 | Citations (PDF) |
| 26 | Relationship between NT-proBNP, echocardiographic abnormalities and functional status in patients with subclinical siabetic cardiomyopathy | 9.4 | 8 | Citations (PDF) |
| 27 | Dietary Sodium and Fluid Restriction for Patients with Heart Failure | 0.5 | 0 | Citations (PDF) |
| 28 | Patiromer for Heart Failure Medication Optimization in Patients With Current or Past Hyperkalemia | 4.4 | 4 | Citations (PDF) |
| 29 | Machine Learning For Risk Prediction After Heart Failure Emergency Department Visit or Hospital Admission Using Administrative Health Data | 5.8 | 4 | Citations (PDF) |
| 30 | Sodium Restriction in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomized Clinical Trials | 4.4 | 43 | Citations (PDF) |
| 31 | Setting the Diagnosis of Heart Failure | 4.4 | 1 | Citations (PDF) |
| 32 | Towards artificial intelligence-based learning health system for population-level mortality prediction using electrocardiograms | 10.4 | 30 | Citations (PDF) |
| 33 | Time to Triple Therapy in Patients With de Novo Heart Failure With Reduced Ejection Fraction: a Population-Based Study | 1.8 | 11 | Citations (PDF) |
| 34 | Clinical Implications of Negatively Adjudicated Heart Failure Events: Data From the VICTORIA Study | 18.0 | 6 | Citations (PDF) |
| 35 | Response by Colin-Ramirez et al to Letter Regarding Article, “Sodium Restriction in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomized Clinical Trials” | 4.4 | 0 | Citations (PDF) |
| 36 | Patients acceptance and comprehension to written and verbal consent (PAC–VC) | 2.4 | 11 | Citations (PDF) |
| 37 | Predicting Heart Failure With Reduced or Preserved Ejection Fraction From Health Records | 4.4 | 1 | Citations (PDF) |
| 38 | Right Ventricular Systolic Pressure Trajectory as a Predictor of Hospitalization and Mortality in Patients With Chronic Heart Failure | 1.6 | 8 | Citations (PDF) |
| 39 | Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial | 4.4 | 21 | Citations (PDF) |
| 40 | The Need for ib r ddition in ymp omatic eart ailure (FEAST-HF): A Randomized Controlled Pilot Trial | 1.6 | 2 | Citations (PDF) |
| 41 | Evolution of NT-proBNP During Prerandomization Screening in VICTORIA: Implications for Clinical Outcomes and Efficacy of Vericiguat | 4.4 | 3 | Citations (PDF) |
| 42 | Kidney function monitoring and trajectories in patients with atrial fibrillation | 1.3 | 1 | Citations (PDF) |
| 43 | Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial | 33.0 | 178 | Citations (PDF) |
| 44 | Do Heart Failure Biomarkers Influence Heart Failure Treatment Response? | 2.9 | 4 | Citations (PDF) |
| 45 | Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction | 18.0 | 63 | Citations (PDF) |
| 46 | Cardiac and cardiometabolic phenotyping of trastuzumab-mediated cardiotoxicity: a secondary analysis of the MANTICORE trial | 4.0 | 38 | Citations (PDF) |
| 47 | Prevalence of Cardiovascular Disease in a Population-Based Cohort of High-Cost Healthcare Services Users | 1.6 | 2 | Citations (PDF) |
| 48 | The Incidence and Prevalence of Cardiac Amyloidosis in a Large Community-Based Cohort in Alberta, Canada | 1.8 | 13 | Citations (PDF) |
| 49 | Concurrent use of P-glycoprotein or Cytochrome 3A4 drugs and non-vitamin K antagonist oral anticoagulants in non-valvular atrial fibrillation | 3.7 | 9 | Citations (PDF) |
| 50 | Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial | 4.0 | 7 | Citations (PDF) |
| 51 | Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine | 6.2 | 56 | Citations (PDF) |
| 52 | The Influence of Comorbidities on Achieving an N-Terminal Pro-B-Type Natriuretic Peptide Target: A Secondary Analysis of the GUIDE-IT Trial | 3.1 | 7 | Citations (PDF) |
| 53 | Automated interpretation of systolic and diastolic function on the echocardiogram: a multicohort study | 14.8 | 176 | Citations (PDF) |
| 54 | Exploring the pragmatic-explanatory spectrum across cardiovascular clinical trials | 1.6 | 4 | Citations (PDF) |
| 55 | 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure | 7.3 | 1,971 | Citations (PDF) |
| 56 | Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry | 1.8 | 46 | Citations (PDF) |
| 57 | Heart Failure with Mildly Reduced Ejection Fraction: Retrospective Study of Ejection Fraction Trajectory Risk | 3.1 | 8 | Citations (PDF) |
| 58 | Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF | 4.4 | 21 | Citations (PDF) |
| 59 | Fluid Restriction: Time to Let it Flow? | 1.8 | 4 | Citations (PDF) |
| 60 | Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial | 62.1 | 159 | Citations (PDF) |
| 61 | Nationwide Study of Sex Differences in Incident Heart Failure in Newly Diagnosed Nonvalvular Atrial Fibrillation | 1.6 | 3 | Citations (PDF) |
| 62 | Assessing race and ethnicity differences in outcomes based on GDMT and target NT-proBNP in patients with heart failure with reduced ejection fraction: An analysis of the GUIDE-IT study | 5.6 | 3 | Citations (PDF) |
| 63 | Epidemiology of Worsening Heart Failure in a Population-based Cohort from Alberta, Canada: Evaluating Eligibility for Treatment With Vericiguat | 1.8 | 16 | Citations (PDF) |
| 64 | Clinical Prediction Models for Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta‐Analysis | 4.0 | 24 | Citations (PDF) |
| 65 | Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial | 4.4 | 31 | Citations (PDF) |
| 66 | Clinical risk, sociodemographic factors, and SARS-CoV-2 infection over time in Ontario, Canada | 3.4 | 11 | Citations (PDF) |
| 67 | Proposal for an Ambulatory Heart Failure Management Curriculum for Cardiology Residency Training Programs | 1.6 | 3 | Citations (PDF) |
| 68 | Sequential Evaluation of NT-proBNP in Heart Failure | 4.4 | 30 | Citations (PDF) |
| 69 | Clinical Phenotypes of Heart Failure across the spectrum of Ejection Fraction: A Cluster Analysis | 3.0 | 5 | Citations (PDF) |
| 70 | Trends in Uptake and Adherence to Oral Anticoagulation for Patients With Incident Atrial Fibrillation at High Stroke Risk Across Health Care Settings | 4.0 | 12 | Citations (PDF) |
| 71 | Use of Guideline-Directed Medical Therapy in Patients Aged ≥ 65 Years After the Diagnosis of Heart Failure: A Canadian Population-Based Study | 1.6 | 24 | Citations (PDF) |
| 72 | Harnessing Electronic Medical Records in Cardiovascular Clinical Practice and Research | 2.0 | 3 | Citations (PDF) |
| 73 | A formal validation of a deep learning-based automated workflow for the interpretation of the echocardiogram | 13.7 | 107 | Citations (PDF) |
| 74 | Left atrial remodelling, mid-regional pro-atrial natriuretic peptide, and prognosis across a range of ejection fractions in heart failure | 1.4 | 13 | Citations (PDF) |
| 75 | Physician Perspectives on the Diagnosis and Management of Heart Failure With Preserved Ejection Fraction | 1.6 | 13 | Citations (PDF) |
| 76 | Plasma Volume Status and Its Association With In-Hospital and Postdischarge Outcomes in Decompensated Heart Failure | 1.8 | 10 | Citations (PDF) |
| 77 | Evidence-Based Management of Acute Heart Failure | 2.6 | 23 | Citations (PDF) |
| 78 | CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction | 2.6 | 264 | Citations (PDF) |
| 79 | Differences in NT‐proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction | 4.0 | 12 | Citations (PDF) |
| 80 | Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design | 4.4 | 43 | Citations (PDF) |
| 81 | Sex Differences in Clinical Course and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure | 4.4 | 44 | Citations (PDF) |
| 82 | Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries | 18.0 | 269 | Citations (PDF) |
| 83 | Feasibility of Incorporating Voice Technology and Virtual Assistants in Cardiovascular Care and Clinical Trials | 1.7 | 18 | Citations (PDF) |
| 84 | Intercountry Differences in Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure | 4.4 | 8 | Citations (PDF) |
| 85 | Cost‐Utility of Catheter Ablation for Atrial Fibrillation in Patients with Heart Failure: An Economic Evaluation | 4.0 | 24 | Citations (PDF) |
| 86 | Effect of patient‐centered transitional care services on patient‐reported outcomes in heart failure: sex‐specific analysis of the
PACT‐HF
randomized controlled trial | 7.3 | 33 | Citations (PDF) |
| 87 | Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure | 9.6 | 60 | Citations (PDF) |
| 88 | Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA) | 18.0 | 41 | Citations (PDF) |
| 89 | Participation in a Heart Failure Clinical Trial | 4.4 | 19 | Citations (PDF) |
| 90 | 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure | 2.2 | 11,961 | Citations (PDF) |
| 91 | Impact of Atrial Fibrillation Case Volume in the Emergency Department on Early and Late Outcomes of Patients With New Atrial Fibrillation | 1.5 | 3 | Citations (PDF) |
| 92 | Clinical Phenotypes in Patients With Type 2 Diabetes Mellitus: Characteristics, Cardiovascular Outcomes and Treatment Strategies | 2.9 | 17 | Citations (PDF) |
| 93 | Is There Any Interaction Between Sex and Renal Function Change During Hospital Stay in Patients Hospitalized With Acute Heart Failure? | 1.8 | 5 | Citations (PDF) |
| 94 | Cardiac Remodelling Predicts Outcome in Patients with Chronic Heart Failure | 3.1 | 24 | Citations (PDF) |
| 95 | Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial | 1.8 | 13 | Citations (PDF) |
| 96 | Chloride in Heart Failure | 4.4 | 77 | Citations (PDF) |
| 97 | Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial | 4.0 | 60 | Citations (PDF) |
| 98 | Ambulance use, distance and outcomes in patients with suspected cardiovascular disease: a registry-based geographic information system study | 1.0 | 19 | Citations (PDF) |
| 99 | Role of Sodium-Glucose Cotransporter-2 Inhibition in the Treatment of Adults With Heart Failure | 1.8 | 2 | Citations (PDF) |
| 100 | All for one, but not one for all | 2.2 | 1 | Citations (PDF) |
| 101 | OUTSMART HF | 18.0 | 29 | Citations (PDF) |
| 102 | Design and Region-Specific Adaptation of the Dietary Intervention Used in the SODIUM-HF Trial: A Multicentre Study | 1.6 | 6 | Citations (PDF) |
| 103 | Impact of cardiology follow-up care on treatment and outcomes of patients with new atrial fibrillation discharged from the emergency department | 2.0 | 22 | Citations (PDF) |
| 104 | Eligibility of Sodium–glucose Co-Transporter-2 Inhibitors Among Patients with Diabetes Mellitus Admitted for Heart Failure | 3.1 | 8 | Citations (PDF) |
| 105 | N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes | 4.4 | 130 | Citations (PDF) |
| 106 | Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction | 16.5 | 272 | Citations (PDF) |
| 107 | Is There a Sex Gap in Surviving an Acute Coronary Syndrome or Subsequent Development of Heart Failure? | 18.0 | 68 | Citations (PDF) |
| 108 | Layer-specific strain in patients with heart failure using cardiovascular magnetic resonance: not all layers are the same | 4.3 | 33 | Citations (PDF) |
| 109 | Non‐vitamin K antagonist oral anticoagulant (NOAC) use and dosing in Canadian practice: Insights from the optimising pharmacotherapy in the management approach to lowering risk in atrial fibrillation (OPTIMAL AF) Programme | 3.0 | 7 | Citations (PDF) |
| 110 | Change of Health‐Related Quality of Life Over Time and Its Association With Patient Outcomes in Patients With Heart Failure | 4.0 | 47 | Citations (PDF) |
| 111 | Comparative Effectiveness of Primary Prevention Implantable Cardioverter‐Defibrillators in Older Heart Failure Patients With Diabetes Mellitus | 4.0 | 2 | Citations (PDF) |
| 112 | Low Prevalence of Transcatheter Mitral Valve Repair Eligibility in a Community Heart Failure Population | 4.4 | 5 | Citations (PDF) |
| 113 | Optimizing Access to Heart Failure Care in Canada During the COVID-19 Pandemic | 2.6 | 22 | Citations (PDF) |
| 114 | Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) | 2.2 | 71 | Citations (PDF) |
| 115 | A multinational registry to study the characteristics and outcomes of heart failure patients: The global congestive heart failure (G-CHF) registry | 2.9 | 62 | Citations (PDF) |
| 116 | The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions | 2.2 | 67 | Citations (PDF) |
| 117 | The Status of Specialized Ambulatory Heart Failure Care in Canada: A Joint Canadian Heart Failure Society and Canadian Cardiovascular Society Heart Failure Guidelines Survey | 1.6 | 16 | Citations (PDF) |
| 118 | The Burden of Non-Cardiac Comorbidities and Association with Clinical Outcomes in an Acute Heart Failure Trial – Insights from ASCEND-HF | 7.3 | 42 | Citations (PDF) |
| 119 | Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | 34.5 | 1,220 | Citations (PDF) |
| 120 | Circulating Troponin and Further Left Ventricular Ejection Fraction Improvement in Patients with Previously Recovered Left Ventricular Ejection Fraction | 3.1 | 7 | Citations (PDF) |
| 121 | Cardiovascular disease burden in adult patients with cancer: An 11-year nationwide population-based cohort study | 2.2 | 50 | Citations (PDF) |
| 122 | Underrepresentation of Women in Cardiovascular Randomized Clinical Trials | 2.6 | 5 | Citations (PDF) |
| 123 | A Novel In-hospital Congestion Score to Risk Stratify Patients Admitted for Worsening Heart Failure (from ASCEND-HF) | 2.0 | 8 | Citations (PDF) |
| 124 | CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis | 2.6 | 109 | Citations (PDF) |
| 125 | Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial | 11.1 | 126 | Citations (PDF) |
| 126 | Elevated Blood Pressure and Associations with Sodium Intake Among Multiethnic Youth in Edmonton, Canada: Findings from WHY ACT NOW | 2.3 | 3 | Citations (PDF) |
| 127 | The Effect of Carotid Chemoreceptor Inhibition on Exercise Tolerance in Chronic Heart Failure | 2.8 | 10 | Citations (PDF) |
| 128 | 2017 Guidelines for the management of heart failure by pharmacists | 0.9 | 4 | Citations (PDF) |
| 129 | Screening and Initiating Supportive Care in Patients With Heart Failure | 2.4 | 8 | Citations (PDF) |
| 130 | Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection | 2.3 | 74 | Citations (PDF) |
| 131 | Trends in the Explanatory or Pragmatic Nature of Cardiovascular Clinical Trials Over 2 Decades | 11.1 | 40 | Citations (PDF) |
| 132 | Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction | 2.3 | 86 | Citations (PDF) |
| 133 | Quantification of lung water in heart failure using cardiovascular magnetic resonance imaging | 4.3 | 24 | Citations (PDF) |
| 134 | A Population-Based Study of Device Eligibility, Use, and Reasons for Nonimplantation in Patients at Heart Function Clinics | 1.6 | 4 | Citations (PDF) |
| 135 | Empirical Insights When Defining the Population Burden of Atrial Fibrillation and Oral Anticoagulation Utilization Using Administrative Data | 2.6 | 14 | Citations (PDF) |
| 136 | The Relationship Between Heart-Failure Hospitalization and Mortality in Patients Receiving Transcatheter Aortic Valve Replacement | 2.6 | 14 | Citations (PDF) |
| 137 | Rationale and Design of the VITALITY-HFpEF Trial | 4.4 | 43 | Citations (PDF) |
| 138 | External Validation and Refinement of Emergency Heart Failure Mortality Risk Grade Risk Model in Patients With Heart Failure in the Emergency Department | 1.6 | 14 | Citations (PDF) |
| 139 | External Validation of the H
2
F-PEF Model in Diagnosing Patients With Heart Failure and Preserved Ejection Fraction | 18.0 | 64 | Citations (PDF) |
| 140 | High vs. Low Oxygen Therapy in Patients with Acute Heart Failure: HiLo-HF Pilot Trial | 3.1 | 22 | Citations (PDF) |
| 141 | Incremental costs of high intensive care utilisation in patients hospitalised with heart failure | 1.0 | 7 | Citations (PDF) |
| 142 | Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study | 2.2 | 113 | Citations (PDF) |
| 143 | Clinical Factors Related to Morbidity and Mortality in High-Risk Heart Failure Patients: The GUIDE-IT Predictive Model and Risk Score | 7.3 | 46 | Citations (PDF) |
| 144 | Elevated pre-transplant left ventricular end-diastolic pressure increases primary graft dysfunction risk in double lung transplant recipients | 1.1 | 20 | Citations (PDF) |
| 145 | The Effects of Resveratrol in Patients with Cardiovascular Disease and Heart Failure: A Narrative Review | 4.4 | 176 | Citations (PDF) |
| 146 | Update on the diagnosis and management of acute heart failure | 1.6 | 7 | Citations (PDF) |
| 147 | Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight | 18.0 | 102 | Citations (PDF) |
| 148 | Titration and Tolerability of Sacubitril/Valsartan for Patients With Heart Failure in Clinical Practice | 2.0 | 20 | Citations (PDF) |
| 149 | NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF | 4.4 | 101 | Citations (PDF) |
| 150 | Frailty modelling for multitype recurrent events in clinical trials | 0.8 | 4 | Citations (PDF) |
| 151 | Insights on the Use of Twitter at the Canadian Cardiovascular Congress | 2.6 | 4 | Citations (PDF) |
| 152 | Interaction of Body Mass Index on the Association Between N‐Terminal‐Pro‐b‐Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND‐HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) | 4.0 | 14 | Citations (PDF) |
| 153 | Use of Direct Oral Anticoagulants in Canadian Primary Care Practice 2010–2015: A Cohort Study From the Canadian Primary Care Sentinel Surveillance Network | 4.0 | 22 | Citations (PDF) |
| 154 | Sudden Cardiac Death After Acute Heart Failure Hospital Admission: Insights from ASCEND-HF | 7.3 | 35 | Citations (PDF) |
| 155 | Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure | 4.4 | 6 | Citations (PDF) |
| 156 | A Prospective Evaluation of the Established Criteria for Heart Failure with Preserved Ejection Fraction Using the Alberta HEART Cohort | 3.1 | 11 | Citations (PDF) |
| 157 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator | 4.4 | 200 | Citations (PDF) |
| 158 | Prediction of Early Adverse Events in Emergency Department Patients With Acute Heart Failure: A Systematic Review | 2.6 | 19 | Citations (PDF) |
| 159 | Aetiology, Timing and Clinical Predictors of Early vs. Late Readmission Following Index Hospitalization for Acute Heart Failure: Insights from ASCEND-HF | 7.3 | 57 | Citations (PDF) |
| 160 | Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure | 2.3 | 30 | Citations (PDF) |
| 161 | Acute Coronary Syndromes and Heart Failure Critical Care Units Utilization and Outcomes in Teaching and Community Hospitals: A National Population-Based Analysis | 2.6 | 2 | Citations (PDF) |
| 162 | Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points | 4.1 | 18 | Citations (PDF) |
| 163 | Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 updateCmaj, 2018, 190, E1192-E1206 | 1.2 | 52 | Citations (PDF) |
| 164 | Impact of contrast echocardiography on accurate discrimination of specific degree of left ventricular systolic dysfunction and comparison with cardiac magnetic resonance imaging | 0.9 | 15 | Citations (PDF) |
| 165 | Comparison of Angiotensin‐Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Management Strategies Before Cardiac Surgery: A Pilot Randomized Controlled Registry Trial | 4.0 | 43 | Citations (PDF) |
| 166 | Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND‐HF | 2.0 | 30 | Citations (PDF) |
| 167 | Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure | 4.4 | 159 | Citations (PDF) |
| 168 | Examining the Influence of Component Outcomes on the Composite at the Design Stage | 4.1 | 1 | Citations (PDF) |
| 169 | Implantable Cardioverter-Defibrillators in Heart Failure Patients with Reduced Ejection Fraction and Diabetes | 7.3 | 30 | Citations (PDF) |
| 170 | Rationale and design of the Study of Dietary Intervention Under 100 MMOL in Heart Failure (SODIUM-HF) | 2.9 | 17 | Citations (PDF) |
| 171 | Reply to McClure et al.—Reader Commentary on 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure | 2.6 | 0 | Citations (PDF) |
| 172 | Initial Rhythm and Resuscitation Outcomes for Patients Developing Cardiac Arrest in Hospital | 2.5 | 21 | Citations (PDF) |
| 173 | Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF) | 1.8 | 22 | Citations (PDF) |
| 174 | Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation | 18.0 | 44 | Citations (PDF) |
| 175 | Effects of age, gender, and risk‐factors for heart failure on native myocardial T1 and extracellular volume fraction using the SASHA sequence at 1.5T | 3.4 | 13 | Citations (PDF) |
| 176 | The high cost of critical care unit over-utilization for patients with NSTE ACS | 2.9 | 21 | Citations (PDF) |
| 177 | Composite End Points in Clinical Trials of Heart Failure Therapy | 4.4 | 19 | Citations (PDF) |
| 178 | Interprovincial Differences in Canadian Coronary Care Unit Resource Use and Outcomes | 2.6 | 15 | Citations (PDF) |
| 179 | Association Between Diabetes During Pregnancy and Peripartum Cardiomyopathy: A Population-Level Analysis of 309,825 Women | 2.6 | 24 | Citations (PDF) |
| 180 | Identifying Low‐risk Patients for Early Discharge From Emergency Department Without Using Subjective Descriptions of Chest Pain: Insights From Providing Rapid Out of Hospital Acute Cardiovascular Treatment (<scp>PROACT</scp>) 3 and 4 Trials | 1.7 | 3 | Citations (PDF) |
| 181 | Letter by Brown and Ezekowitz Regarding Article, “Development and Evolution of a Hierarchical Clinical Composite End Point for the Evaluation of Drugs and Devices for Acute and Chronic Heart Failure: A 20-Year Perspective” | 18.0 | 4 | Citations (PDF) |
| 182 | Characterization of hemodynamically stable acute heart failure patients requiring a critical care unit admission: Derivation, validation, and refinement of a risk score | 2.9 | 5 | Citations (PDF) |
| 183 | Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF) | 2.2 | 140 | Citations (PDF) |
| 184 | Impact of Current Versus Previous Cardiac Resynchronization Therapy Guidelines on the Proportion of Patients With Heart Failure Eligible for Therapy | 4.4 | 12 | Citations (PDF) |
| 185 | Multitype Events and the Analysis of Heart Failure Readmissions | 4.1 | 3 | Citations (PDF) |
| 186 | Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure | 2.3 | 86 | Citations (PDF) |
| 187 | Dietary Self-management in Heart Failure: High Tech or High Touch? | 0.5 | 6 | Citations (PDF) |
| 188 | 2016 AHA/ACC Clinical Performance and Quality Measures for Prevention of Sudden Cardiac Death | 2.3 | 28 | Citations (PDF) |
| 189 | Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes | 4.4 | 111 | Citations (PDF) |
| 190 | 2016 AHA/ACC Clinical Performance and Quality Measures for Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures | 4.1 | 14 | Citations (PDF) |
| 191 | The Impact and Implications of Twitter for Cardiovascular Medicine | 1.8 | 18 | Citations (PDF) |
| 192 | Effect of Natriuretic Peptide–Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction | 16.5 | 503 | Citations (PDF) |
| 193 | Ivabradine in Heart Failure | 4.4 | 26 | Citations (PDF) |
| 194 | Letter by Kaul et al Regarding Article, “Age-Specific Trends in Incidence, Mortality, and Comorbidities of Heart Failure in Denmark, 1995 to 2012” | 18.0 | 0 | Citations (PDF) |
| 195 | 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure | 2.6 | 610 | Citations (PDF) |
| 196 | Heart Failure in Young Adults Is Associated With High Mortality: A Contemporary Population-Level Analysis | 2.6 | 33 | Citations (PDF) |
| 197 | Differentiating Heart Failure Phenotypes Using Sex-Specific Transcriptomic and Proteomic Biomarker Panels | 3.1 | 35 | Citations (PDF) |
| 198 | A Network Analysis to Compare Biomarker Profiles in Patients with and without Diabetes Mellitus in Acute Heart Failure | 7.3 | 59 | Citations (PDF) |
| 199 | Comparison of two commonly used clinical cognitive screening tests to diagnose mild cognitive impairment in heart failure with the golden standard European Consortium Criteria | 2.2 | 44 | Citations (PDF) |
| 200 | Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF | 2.8 | 40 | Citations (PDF) |
| 201 | Power and Sample Size Estimation for Nonparametric Composite Endpoints: Practical Implementation using Data Simulations | 0.3 | 2 | Citations (PDF) |
| 202 | Cognitive decline in heart failure | 3.3 | 64 | Citations (PDF) |
| 203 | Salt in the diet in patients with heart failure | 1.6 | 14 | Citations (PDF) |
| 204 | The Clinical Course of Health Status and Association with Outcomes in Patients Hospitalized for Heart Failure: Insights from ASCEND-HF | 7.3 | 49 | Citations (PDF) |
| 205 | Insights into the Importance of the Electrocardiogram in Patients with Acute Heart Failure | 7.3 | 30 | Citations (PDF) |
| 206 | Cost Effectiveness of Eplerenone for the Treatment of Systolic Heart Failure with Mild Symptoms in Alberta, Canada | 2.5 | 8 | Citations (PDF) |
| 207 | Liver Function Tests in Patients with Acute Heart Failure and Associated Outcomes: Insights from ASCEND-HF | 7.3 | 62 | Citations (PDF) |
| 208 | Nesiritide in Patients Hospitalized for Acute Heart Failure: Does Timing Matter? Implication for Future Acute Heart Failure Trials | 7.3 | 14 | Citations (PDF) |
| 209 | Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial | 62.1 | 273 | Citations (PDF) |
| 210 | The current and future financial burden of hospital admissions for heart failure in Canada: a cost analysis | 1.5 | 104 | Citations (PDF) |
| 211 | Guía ESC 2016 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica | 1.1 | 122 | Citations (PDF) |
| 212 | Changes in dietary intake and nutritional status associated with a significant reduction in sodium intake in patients with heart failure. A sub-analysis of the SODIUM-HF pilot study | 0.7 | 29 | Citations (PDF) |
| 213 | The ‘obesity paradox’ in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial | 2.2 | 225 | Citations (PDF) |
| 214 | Letter by McAlister and Ezekowitz Regarding Article, “Temporal Trends and Variation in Early Scheduled Follow-Up After a Hospitalization for Heart Failure: Findings From Get With the Guidelines-Heart Failure” | 4.4 | 0 | Citations (PDF) |
| 215 | Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points | 4.4 | 20 | Citations (PDF) |
| 216 | Early Follow-Up After a Heart Failure Exacerbation | 4.4 | 69 | Citations (PDF) |
| 217 | Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine | 11.1 | 93 | Citations (PDF) |
| 218 | Arrival by ambulance in acute heart failure: insights into the mode of presentation from Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND-HF) | 1.9 | 14 | Citations (PDF) |
| 219 | Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF Trial) | 1.8 | 29 | Citations (PDF) |
| 220 | Factors Associated With Natriuretic Peptide Testing in Patients Presenting to Emergency Departments With Suspected Heart Failure | 2.6 | 10 | Citations (PDF) |
| 221 | Oxygen Therapy in Patients With Acute Heart Failure | 4.4 | 78 | Citations (PDF) |
| 222 | Alignment of site versus adjudication committee–based diagnosis with patient outcomes: Insights from the Providing Rapid Out of Hospital Acute Cardiovascular Treatment 3 trial | 1.8 | 13 | Citations (PDF) |
| 223 | Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial) | 1.8 | 57 | Citations (PDF) |
| 224 | Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure | 2.3 | 220 | Citations (PDF) |
| 225 | Coenzyme Q10 and Heart Failure | 4.4 | 134 | Citations (PDF) |
| 226 | Dichotomous Relationship Between Age and 30-Day Death or Rehospitalization in Heart Failure Patients Admitted With Acute Decompensated Heart Failure: Results From the ASCEND-HF Trial | 1.8 | 11 | Citations (PDF) |
| 227 | Do stable non–ST-segment elevation acute coronary syndromes require admission to coronary care units? | 2.9 | 36 | Citations (PDF) |
| 228 | Composite End Points in Acute Heart Failure Research: Data Simulations Illustrate the Limitations | 2.6 | 10 | Citations (PDF) |
| 229 | Canadian Cardiovascular Society Quality Indicators for Heart Failure | 2.6 | 14 | Citations (PDF) |
| 230 | Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial | 4.0 | 60 | Citations (PDF) |
| 231 | Providing Rapid Out of Hospital Acute Cardiovascular Treatment 4 (PROACT‐4) | 4.0 | 31 | Citations (PDF) |
| 232 | Is Heart Rate a Risk Marker in Patients with Chronic Heart Failure and Concomitant Atrial Fibrillation? Results from the MAGGIC Meta-Analysis | 7.3 | 55 | Citations (PDF) |
| 233 | The Prognostic Importance of Changes in Renal Function during Treatment for Acute Heart Failure Depends on Admission Renal Function | 2.3 | 12 | Citations (PDF) |
| 234 | Impact of Rural Residence on Warfarin Use and Clinical Events in Patients with Non-Valvular Atrial Fibrillation: A Canadian Population Based Study | 2.3 | 11 | Citations (PDF) |
| 235 | Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) | 2.9 | 40 | Citations (PDF) |
| 236 | Variation in Critical Care Unit Admission Rates and Outcomes for Patients With Acute Coronary Syndromes or Heart Failure Among High‐ and Low‐Volume Cardiac Hospitals | 4.0 | 50 | Citations (PDF) |
| 237 | Acute Heart Failure and Atrial Fibrillation: Insights From the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND‐HF) Trial | 4.0 | 29 | Citations (PDF) |
| 238 | The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: Anemia, Biomarkers, and Recent Therapeutic Trial Implications | 2.6 | 100 | Citations (PDF) |
| 239 | Incorporating patient preferences into clinical trial design: Results of the Opinions of Patients on Treatment Implications of New Studies (OPTIONS) project | 2.9 | 27 | Citations (PDF) |
| 240 | Peripheral chemoreceptor control of cardiovascular function at rest and during exercise in heart failure patients | 2.8 | 21 | Citations (PDF) |
| 241 | Heart Failure Therapeutics on the Basis of a Biased Ligand of the Angiotensin-2 Type 1 Receptor | 4.4 | 72 | Citations (PDF) |
| 242 | Loop Diuretic Dose Adjustments after a Hospitalization for Heart Failure: Insights From ASCEND-HF | 7.3 | 24 | Citations (PDF) |
| 243 | Correlation between peak expiratory flow rate and NT-proBNP in patients with acute heart failure. An analysis from ASCEND-HF trial | 2.2 | 2 | Citations (PDF) |
| 244 | The future of cardiovascular clinical research in North America and beyond—addressing challenges and leveraging opportunities through unique academic and grassroots collaborations | 2.9 | 16 | Citations (PDF) |
| 245 | Assessing the Use of International Classification of Diseases-10th Revision Codes From the Emergency Department for the Identification of Acute Heart Failure | 4.4 | 50 | Citations (PDF) |
| 246 | Diuretic response in acute heart failure—an analysis from ASCEND-HF | 2.9 | 133 | Citations (PDF) |
| 247 | Association Between Self-reported Adherence to a Low-Sodium Diet and Dietary Habits Related to Sodium Intake in Heart Failure Patients | 1.4 | 25 | Citations (PDF) |
| 248 | Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models | 2.9 | 68 | Citations (PDF) |
| 249 | Estimates of Dietary Sodium Consumption in Patients With Chronic Heart Failure | 1.8 | 18 | Citations (PDF) |
| 250 | Heart failure guidelines failCmaj, 2015, 187, 912.2-912 | 1.2 | 0 | Citations (PDF) |
| 251 | The long-term effects of dietary sodium restriction on clinical outcomes in patients with heart failure. The SODIUM-HF (Study of Dietary Intervention Under 100 mmol in Heart Failure): A pilot study | 2.9 | 65 | Citations (PDF) |
| 252 | Early Management of Patients With Acute Heart Failure: State of the Art and Future Directions—A Consensus Document from the SAEM/HFSA Acute Heart Failure Working Group | 1.7 | 43 | Citations (PDF) |
| 253 | Metabolomic Fingerprint of Heart Failure with Preserved Ejection Fraction | 2.3 | 202 | Citations (PDF) |
| 254 | Heart Failure Re-Admission: Measuring the Ever Shortening Gap between Repeat Heart Failure Hospitalizations | 2.3 | 36 | Citations (PDF) |
| 255 | Hypotension During Hospitalization for Acute Heart Failure Is Independently Associated With 30-Day Mortality | 4.4 | 55 | Citations (PDF) |
| 256 | Nesiritide, Renal Function, and Associated Outcomes During Hospitalization for Acute Decompensated Heart Failure | 18.0 | 45 | Citations (PDF) |
| 257 | The association between meteorological events and acute heart failure: New insights from ASCEND-HF | 2.2 | 10 | Citations (PDF) |
| 258 | The Relationship between Left Ventricular Ejection Fraction and Mortality in Patients with Acute Heart Failure: Insights from the ASCEND-HF Trial | 7.3 | 68 | Citations (PDF) |
| 259 | Smoking status and survival: impact on mortality of continuing to smoke one year after the angiographic diagnosis of coronary artery disease, a prospective cohort study | 2.0 | 24 | Citations (PDF) |
| 260 | Representativeness of RELAX-AHF Clinical Trial Population in Acute Heart Failure | 4.1 | 39 | Citations (PDF) |
| 261 | Determinants of Early Readmission After Hospitalization for Heart Failure | 2.6 | 45 | Citations (PDF) |
| 262 | Influence of heart failure symptoms and ejection fraction on short- and long-term outcomes for older patients with non–ST-segment elevation myocardial infarction | 2.9 | 20 | Citations (PDF) |
| 263 | Risk Stratification in Acute Heart Failure | 2.6 | 42 | Citations (PDF) |
| 264 | The 2013 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Rehabilitation and Exercise and Surgical Coronary Revascularization | 2.6 | 52 | Citations (PDF) |
| 265 | Acute decompensated heart failure patients admitted to critical care units: Insights from ASCEND-HF | 2.2 | 15 | Citations (PDF) |
| 266 | Rates and reasons for device-based guideline eligibility in patients with heart failure | 2.7 | 14 | Citations (PDF) |
| 267 | Rationale and Design of the GUIDE-IT Study | 4.4 | 115 | Citations (PDF) |
| 268 | Trends in death attributed to myocardial infarction, heart failure and pulmonary embolism in Europe and Canada over the last decade | 0.5 | 23 | Citations (PDF) |
| 269 | Dietary fatty acids intake and mortality in patients with heart failure | 2.7 | 28 | Citations (PDF) |
| 270 | Providing Rapid Out of Hospital Acute Cardiovascular Treatment 3 (PROACT-3) | 2.6 | 12 | Citations (PDF) |
| 271 | Which risk score best predicts perioperative outcomes in nonvalvular atrial fibrillation patients undergoing noncardiac surgery? | 2.9 | 23 | Citations (PDF) |
| 272 | Mortality Outcomes Among Status Aboriginals and Whites With Heart Failure | 2.6 | 9 | Citations (PDF) |
| 273 | Novel Pharmacologic Therapies in Development for Acute Decompensated Heart Failure | 2.9 | 4 | Citations (PDF) |
| 274 | Effects of Nesiritide and Predictors of Urine Output in Acute Decompensated Heart Failure | 2.3 | 87 | Citations (PDF) |
| 275 | Similarities and Differences in Patient Characteristics Between Heart Failure Registries Versus Clinical Trials | 2.9 | 17 | Citations (PDF) |
| 276 | Myocardial Deformation Analysis in Contrast Echocardiography: First Results Using Two-Dimensional Cardiac Performance Analysis | 3.4 | 8 | Citations (PDF) |
| 277 | Predictors of Early Dyspnoea Relief in Acute Heart Failure and the Association with 30-Day Outcomes: Findings from ASCEND-HF | 7.3 | 41 | Citations (PDF) |
| 278 | Left Ventricular Systolic Dysfunction, Heart Failure, and the Risk of Stroke and Systemic Embolism in Patients With Atrial Fibrillation | 4.4 | 150 | Citations (PDF) |
| 279 | The 2012 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Acute and Chronic Heart Failure | 2.6 | 183 | Citations (PDF) |
| 280 | Differences in Treatment, Outcomes, and Quality of Life Among Patients With Heart Failure in Canada and the United States | 4.4 | 24 | Citations (PDF) |
| 281 | Neither Diabetes nor Glucose-Lowering Drugs Are Associated With Mortality After Noncardiac Surgery in Patients With Coronary Artery Disease or Heart Failure | 2.6 | 9 | Citations (PDF) |
| 282 | The relationship between meteorological conditions and index acute coronary events in a global clinical trial | 2.2 | 15 | Citations (PDF) |
| 283 | Incidence of heart failure and mortality after acute coronary syndromes | 2.9 | 99 | Citations (PDF) |
| 284 | Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: An APEX AMI substudy | 2.2 | 41 | Citations (PDF) |
| 285 | Acute Decompensated Heart Failure: Update on New and Emerging Evidence and Directions for Future Research | 1.8 | 56 | Citations (PDF) |
| 286 | N-Terminal Pro–B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation | 2.3 | 220 | Citations (PDF) |
| 287 | Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial | 2.2 | 184 | Citations (PDF) |
| 288 | Practice-Level Variation in Use of Recommended Medications Among Outpatients With Heart Failure | 4.4 | 36 | Citations (PDF) |
| 289 | Global Variation in Quality of Care Among Patients Hospitalized With Acute Heart Failure in an International Trial | 4.1 | 26 | Citations (PDF) |
| 290 | Changes in Heart Failure Outcomes After a Province-Wide Change in Health Service Provision A Natural Experiment in Alberta, Canada | 4.4 | 32 | Citations (PDF) |
| 291 | Do Countries or Hospitals With Longer Hospital Stays for Acute Heart Failure Have Lower Readmission Rates? | 4.4 | 111 | Citations (PDF) |
| 292 | Impact of physician continuity on death or urgent readmission after discharge among patients with heart failureCmaj, 2013, 185, E681-E689 | 1.2 | 90 | Citations (PDF) |
| 293 | Effect of low‐dose dopamine on cardio‐respiratory physiology in heart failure patients | 0.6 | 0 | Citations (PDF) |
| 294 | Acute Heart Failure | 4.4 | 28 | Citations (PDF) |
| 295 | Testosterone Supplementation in Heart Failure | 4.4 | 186 | Citations (PDF) |
| 296 | Renal Dysfunction in Patients With Heart Failure With Preserved Versus Reduced Ejection Fraction | 4.4 | 190 | Citations (PDF) |
| 297 | Heart Failure Is a Clinically and Densitometrically Independent Risk Factor for Osteoporotic Fractures: Population-Based Cohort Study of 45,509 Subjects | 4.0 | 57 | Citations (PDF) |
| 298 | Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial | 62.1 | 187 | Citations (PDF) |
| 299 | Indications for Cardiac Resynchronization Therapy: 2011 Update From the Heart Failure Society of America Guideline Committee | 1.8 | 97 | Citations (PDF) |
| 300 | Update on Aldosterone Antagonists Use in Heart Failure With Reduced Left Ventricular Ejection Fraction Heart Failure Society of America Guidelines Committee | 1.8 | 52 | Citations (PDF) |
| 301 | Predicting the risk of unplanned readmission or death within 30 days of discharge after a heart failure hospitalization | 2.9 | 149 | Citations (PDF) |
| 302 | Assessment of Dyspnea in Acute Decompensated Heart Failure | 2.3 | 38 | Citations (PDF) |
| 303 | Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial | 1.9 | 23 | Citations (PDF) |
| 304 | The Timing of Implantable Cardioverter-Defibrillator Implantation in Patients with Heart Failure | 2.9 | 1 | Citations (PDF) |
| 305 | Association of global weather changes with acute coronary syndromes: gaining insights from clinical trials data | 2.3 | 8 | Citations (PDF) |
| 306 | Trends in Heart Failure Care: Has the Incident Diagnosis of Heart Failure Shifted from the Hospital to the Emergency Department and Outpatient Clinics? | 7.3 | 130 | Citations (PDF) |
| 307 | Effect of Nesiritide in Patients with Acute Decompensated Heart Failure | 34.5 | 1,205 | Citations (PDF) |
| 308 | The epidemiology of atrial fibrillation in adults depends on locale of diagnosis | 2.9 | 39 | Citations (PDF) |
| 309 | The 2011 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Sleep Apnea, Renal Dysfunction, Mechanical Circulatory Support, and Palliative Care | 2.6 | 142 | Citations (PDF) |
| 310 | Apixaban versus Warfarin in Patients with Atrial Fibrillation | 34.5 | 8,475 | Citations (PDF) |
| 311 | Meta-analysis: Cardiac Resynchronization Therapy for Patients With Less Symptomatic Heart Failure | 9.6 | 120 | Citations (PDF) |
| 312 | Carotid chemoreceptor modulation of blood flow during exercise in healthy humans | 3.4 | 65 | Citations (PDF) |
| 313 | Do Anthropometric Indices Accurately Reflect Directly Measured Body Composition in Men and Women With Chronic Heart Failure? | 2.2 | 24 | Citations (PDF) |
| 314 | The Correlation of Standard Heart Failure Assessment and Palliative Care Questionnaires in a Multidisciplinary Heart Failure Clinic | 0.8 | 42 | Citations (PDF) |
| 315 | Use of Oral Proton Pump Inhibitors is not Associated with Harm in Patients with Chronic Heart Failure in an Ambulatory Setting | 7.3 | 9 | Citations (PDF) |
| 316 | Risk stratification schemes, anticoagulation use and outcomes: the risk–treatment paradox in patients with newly diagnosed non-valvular atrial fibrillationHeart, 2011, 97, 2046-2050 | 3.9 | 76 | Citations (PDF) |
| 317 | The Unrecognized Burden of Osteoporosis-Related Vertebral Fractures in Patients With Heart Failure | 4.4 | 40 | Citations (PDF) |
| 318 | Ethnic differences in 1-year mortality among patients hospitalised with heart failureHeart, 2011, 97, 1048-1053 | 3.9 | 24 | Citations (PDF) |
| 319 | Patterns of Care and Outcomes Differ for Urban Versus Rural Patients With Newly Diagnosed Heart Failure, Even in a Universal Healthcare System | 4.4 | 109 | Citations (PDF) |
| 320 | Mortality and Readmission of Patients With Heart Failure, Atrial Fibrillation, or Coronary Artery Disease Undergoing Noncardiac Surgery | 18.0 | 215 | Citations (PDF) |
| 321 | Resource Use in the Last 6 Months of Life Among Patients With Heart Failure in Canada | 8.1 | 71 | Citations (PDF) |
| 322 | The Prevalence of Natural Health Product Use in Patients with Acute Cardiovascular Disease | 2.3 | 20 | Citations (PDF) |
| 323 | Prediction of cardiogenic shock using plasma B-type natriuretic peptide and the N-terminal fragment of its pro-hormone concentrations in ST elevation myocardial infarction: An analysis from the ASSENT-4 Percutaneous Coronary Intervention Trial | 0.5 | 17 | Citations (PDF) |
| 324 | The epidemiology and management of elderly patients with myocardial infarction or heart failure | 3.3 | 10 | Citations (PDF) |
| 325 | Association between obesity and health-related quality of life in patients with coronary artery disease | 3.0 | 52 | Citations (PDF) |
| 326 | A new pathway? Failure, fragility and fractures | 2.2 | 10 | Citations (PDF) |
| 327 | Association Between Direct Measures of Body Composition and Prognostic Factors in Chronic Heart Failure | 3.7 | 151 | Citations (PDF) |
| 328 | HFSA 2010 Comprehensive Heart Failure Practice Guideline | 1.8 | 1,140 | Citations (PDF) |
| 329 | Comparison of Direct Body Composition Assessment Methods in Patients With Chronic Heart Failure | 1.8 | 26 | Citations (PDF) |
| 330 | Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: A substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trial | 2.9 | 23 | Citations (PDF) |
| 331 | Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy | 2.9 | 32 | Citations (PDF) |
| 332 | Does silent myocardial infarction add prognostic value in ST-elevation myocardial infarction patients without a history of prior myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial | 2.9 | 18 | Citations (PDF) |
| 333 | The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: Heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs | 2.6 | 128 | Citations (PDF) |
| 334 | A Case of Dilated Cardiomyopathy Associated with 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG CoA) Lyase Deficiency | 0.6 | 23 | Citations (PDF) |
| 335 | A Call to Action: Cardiac Palliative Care | 1.3 | 1 | Citations (PDF) |
| 336 | Response to Letter Regarding Article, “Heart Failure Is a Risk Factor for Orthopedic Fracture: A Population-Based Analysis of 16 294 Patients” | 18.0 | 0 | Citations (PDF) |
| 337 | Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysis | 2.2 | 4 | Citations (PDF) |
| 338 | The relationship between body mass index, treatment, and mortality in patients with established coronary artery disease: a report from APPROACH | 2.2 | 128 | Citations (PDF) |
| 339 | Standardizing care for acute decompensated heart failure in a large megatrial: The approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF) | 2.9 | 37 | Citations (PDF) |
| 340 | Declining In-Hospital Mortality and Increasing Heart Failure Incidence in Elderly Patients With First Myocardial Infarction | 2.3 | 341 | Citations (PDF) |
| 341 | Meta-analysis: β-Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure | 9.6 | 458 | Citations (PDF) |
| 342 | Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: Diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials | 2.6 | 82 | Citations (PDF) |
| 343 | Comparison of One-Year Outcome (Death and Rehospitalization) in Hospitalized Heart Failure Patients With Left Ventricular Ejection Fraction >50% Versus Those With Ejection Fraction <50% | 1.8 | 22 | Citations (PDF) |
| 344 | Canadian Cardiovascular Society Consensus Conference guidelines on heart failure – 2008 update: Best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies | 2.6 | 92 | Citations (PDF) |
| 345 | Heart Failure Is a Risk Factor for Orthopedic Fracture | 18.0 | 144 | Citations (PDF) |
| 346 | Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials | 2.2 | 147 | Citations (PDF) |
| 347 | Acute Heart Failure in the Emergency Department: Short and Long-Term Outcomes of Elderly Patients with Heart Failure | 7.3 | 110 | Citations (PDF) |
| 348 | Cardiac Resynchronization Therapy for Patients With Left Ventricular Systolic Dysfunction | 16.5 | 538 | Citations (PDF) |
| 349 | Insights into the change in brain natriuretic peptide after ST-elevation myocardial infarction (STEMI): why should it be better than baseline?This paper is one of a selection of papers published in this Special Issue, entitled Young Investigators' Forum. | 1.8 | 11 | Citations (PDF) |
| 350 | Systematic Review: Implantable Cardioverter Defibrillators for Adults with Left Ventricular Systolic Dysfunction | 9.6 | 151 | Citations (PDF) |
| 351 | Design of a randomized trial of a multidisciplinary team heart failure rapid referral program: Heart failure Evaluation — Acute Referral Team Trial (HEARTT) | 0.9 | 0 | Citations (PDF) |
| 352 | N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction | 2.6 | 26 | Citations (PDF) |
| 353 | Proportion of Patients Followed in a Specialized Heart Failure Clinic Needing an Implantable Cardioverter Defibrillator as Determined by Applying Different Trial Eligibility Criteria | 1.8 | 18 | Citations (PDF) |
| 354 | Impact of specialist follow-up in outpatients with congestive heart failure | 1.2 | 165 | Citations (PDF) |
| 355 | Time-dependent analysis in CHF follow-up | 1.2 | 0 | Citations (PDF) |
| 356 | Angiotensin receptor blockers and risk of myocardial infarction: systematic review | 0.1 | 68 | Citations (PDF) |
| 357 | The Use of β-Blockers in a Tertiary Care Heart Failure Clinic | 8.1 | 43 | Citations (PDF) |
| 358 | Renal Insufficiency and Heart Failure | 18.0 | 681 | Citations (PDF) |
| 359 | Usefulness of spironolactone in a specialized heart failure clinic | 1.8 | 29 | Citations (PDF) |
| 360 | The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease | 2.3 | 341 | Citations (PDF) |
| 361 | Therapeutic exercise for individuals with heart failure: special attention to older women with heart failure | 1.8 | 22 | Citations (PDF) |
| 362 | Systematic Review: Cardiac Resynchronization in Patients with Symptomatic Heart Failure | 9.6 | 281 | Citations (PDF) |
| 363 | Anemia Is Common in Heart Failure and Is Associated With Poor Outcomes | 18.0 | 834 | Citations (PDF) |
| 364 | Implantable Cardioverter Defibrillators in Primary and Secondary Prevention | 9.6 | 239 | Citations (PDF) |
| 365 | Defibrillators and Sudden Death | 9.6 | 0 | Citations (PDF) |
| 366 | Successful cryopreservation of rat islets using ethylene glycol | 0.7 | 3 | Citations (PDF) |
| 367 | CRYOPRESERVATION OF RAT PANCREATIC ISLETS | 2.1 | 23 | Citations (PDF) |
| 368 | Guideline-Directed Medical Therapy Use in the STRONG-HF Trial | 4.4 | 2 | Citations (PDF) |
| 369 | Network Meta-Analysis of Quality of Life in Heart Failure With Reduced Ejection Fraction | 4.4 | 5 | Citations (PDF) |
| 370 | Testing for Coronary Artery Disease in Patients Newly Diagnosed with Heart Failure in Alberta, Canada | 1.6 | 0 | Citations (PDF) |
| 371 | Phenomapping in Heart Failure With Reduced Ejection Fraction to Identify Subpopulations With High Residual Risk: A VICTORIA Substudy | 4.4 | 1 | Citations (PDF) |
| 372 | Functional and Prognostic Implications of Different Iron Deficiency Definitions in Heart Failure | 4.4 | 2 | Citations (PDF) |
| 373 | Outcomes, Safety and Tolerability of Sacubitril-Valsartan over 3 years of Follow-up in Canadian Practice: Insights from the PARTHENON Registry | 1.6 | 1 | Citations (PDF) |
| 374 | Hyperkalemia-Related Heart Failure Therapy Discontinuation and the Association With Outcomes in Patients With Heart Failure | 4.4 | 0 | Citations (PDF) |
| 375 | Re“FINE”ing Our Understanding of Finerenone in Heart Failure Across the Spectrum of Cardio-Kidney-Metabolic Risk | 4.4 | 0 | Citations (PDF) |
| 376 | After cardioversion in AF, continued caffeinated coffee consumption vs. abstinence reduced AF or atrial flutter recurrence at 6 mo | 9.6 | 0 | Citations (PDF) |
| 377 | Machine learning model for predicting improvement in left ventricular systolic function in patients with heart failure and reduced ejection fraction | 0.7 | 0 | Citations (PDF) |
| 378 | Response by Ezekowitz to Letter Regarding Article, “Network Meta-Analysis of Quality of Life in Heart Failure With Reduced Ejection Fraction” | 4.4 | 0 | Citations (PDF) |
| 379 | Effectiveness and safety of sodium-glucose cotransporter-2 inhibitor initiation in sacubitril-valsartan users with heart failure: a population-based cohort study | 4.0 | 0 | Citations (PDF) |
| 380 | The Effect of Vericiguat on Recurrent Heart Failure Hospitalization and Death in Ambulatory HFrEF | 4.4 | 0 | Citations (PDF) |
